DGAT2 and fatty liver disease: As shown in Figure 7C, we observed the mRNA level of DGAT2, which encodes an enzyme that catalyzes the final step in TAG synthesis, was significantly decreased by compound C3 treatment in a dose-dependent manner by 46% under condition of hepatic steatosis (Figure 7C,F).